Saphyr is emerging as the tool that will lead the modernization of the cytogenetics laboratory

SAN DIEGO, Thursday, June 13, 2019 -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, announces a series of presentations at the upcoming European Human Genetics Conference (ESHG), June 15 to 18 in Gothenburg, Sweden.

Erik Holmlin, Ph.D., CEO of Bionano, commented, “Our customers are showing the global community of researchers and clinicians through their ESHG presentations and posters that Saphyr adds a critically needed ability to reliably detect genomic structural variations (SVs). SVs are important drivers of disease and are currently the basis of a number of standard clinical tests. Users are sharing new discoveries made with Saphyr at a record pace and showing how Saphyr will lead the transformation and modernization of the traditional cytogenetics workflow into digital cytogenetics. The record progress presented has been accelerated by widespread adoption of Saphyr and our success in product development, where we have released product improvements that make Bionano data even easier and cheaper to generate and at much higher speeds.”

Bionano will be hosting a satellite workshop on Sunday, June 16th featuring two members of world-leading institutions on their use of Bionano optical mapping for clinical assessment of leukemias and reproductive and developmental disorders, and their ongoing projects exploring the use of this technology to replace a combination of many platforms and tests such as karyotyping, FISH and Chromosomal Microarray Analysis (CMA) with a single assay. Dr. Alexander Hoischen from Radboud University Medical Center will present, “Optical mapping enables next generation cytogenetics – applications in medical genetics,” while Dr. Laila El Khattabi from APHP Cochin Paris Descartes University will discuss, “Using next generation mapping to detect balanced as well as unbalanced structural variants in reproductive and developmental diseases.”

Bionano will be onsite at Booth #332 to discuss Bionano mapping, Saphyr, and findings presented during the various sessions.

Over a half dozen different scientists are presenting on Bionano optical genome mapping data:

Bionano Workshop:

Next-Generation Cytogenetics: High-throughput Mapping of Structural Variation in Cancer and Genetic Disease
Presenting Authors: Sven Bocklandt, PhD, Alexander Hoischen, PhD and Laila El Khattabi, PhD
Date, Time: Sunday, June 16, 7:15pm – 8:45pm CEST
Location: Room A-4 Swedish Exhibition & Congress Center
PgmNR: CS20

Platform Presentations:

Optical mapping of 22q11.2 low copy repeats reveals structural hypervariability
Presenting Author: Lies Vervoort, Department of Human Genetics, KU Leuven, Leuven, Belgium
Date, Time: Monday 17 June, 1:30pm - 1:45pm CEST
PgmNR: C19.3

Electronic Poster Presentation:

Optical Genome Mapping for Detection of Structural Variants in Constitutional Disease
Presenting Author: Alex Hastie, PhD, Bionano Genomics, Inc.
Date, Time: Sunday, 16 June, 9:00am – 5:45pm CEST
PgmNR: E-P16.06

Poster Presentations:

Increasing the value of the Swedish 1000 whole-genome data resource
Presenting Author: A. Ameur, Uppsala University, Uppsala, Sweden
Date, Time: Sunday 16 June, 10:15am – 11:55am CEST
PgmNR: P18.81A

Sensitive Detection of Low Allele Fraction Structural Variants in Clinical Cancer Samples
Presenting Author: Yannick Delpu, PhD, Bionano Genomics, Inc.
Date, Time: Sunday, 16 June, 4:45pm – 5:45pm CEST
PgmNR: P16.10B

Solution-based isolation of ultra-high-molecular weight (UHMW) DNA from fresh/frozen human blood and cultured cells in less than 3 hours
Presenting Author: Goran Pljevaljcic, PhD, Bionano Genomics, Inc
Date, Time: Monday 17 June, 10:15am – 11:15am CEST
PgmNR: P14.040C

Evaluation of the Bionano optical mapping technology as a replacement of conventional cytogenetics in a diagnostic setting
Presenting Author: Charlotte Keith, South East Scotland Genetic Laboratories, Western General Hospital
Date, Time: Monday 17 June, 10:15am -11:15am CEST
PgmNR: P16.23C

Next-generation cytogenetics in medical genetics with high-resolution optical mapping
Presenting Author: Tuomo Mantere, PhD, Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands
Date, Time: Monday 17 June, 10:15am -11:15am CEST
PgmNR: P14.036C

Using multiple sequencing platforms to identify and characterise disease-causing genome alterations
Presenting Author: Giuseppe Gallone, PhD, Max Planck Institute for Molecular Genetics, Berlin, Germany
Date, Time: Monday 17 June, 10:15am – 11:15am CEST
PgmNR: P16.71C

Comprehensive detection of germline and somatic structural mutation in cancer genomes by Bionano Genomics optical mapping
More information about Bionano Genomics is available at www.bionanogenomics.com

About Bionano Genomics
Bionano is a life sciences instrumentation company in the genome analysis space. Bionano develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to drive the adoption of digital cytogenetics, which is designed to be a more systematic, streamlined and industrialized form of traditional cytogenetics. The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools.

Contacts
Company Contact:
Mike Ward, CFO
Bionano Genomics, Inc.
+1 (858) 888-7600
mward@bionanogenomics.com

Investor Relations Contact: Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 775-5956
arr@lifesciadvisors.com

Media Contact:
Kirsten Thomas The Ruth Group
+1 (508) 280-6592
kthomas@theruthgroup.com